PRF Technologies Ltd. (PRFX)
NASDAQ: PRFX · Real-Time Price · USD
0.9616
-0.0584 (-5.73%)
At close: Sep 21, 2026, 4:00 PM EDT
0.9930
+0.0314 (3.27%)
Pre-market: Sep 22, 2026, 8:20 AM EDT
Company Description
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel.
It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.
The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026.
PRF Technologies Ltd. was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel.
PRF Technologies Ltd.
| Country | Israel |
| Founded | 2007 |
| IPO Date | Sep 1, 2020 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Efraim Cohen-Arazi |
Contact Details
Address: 65 Yigal Alon St. Tel Aviv, 6744316 Israel | |
| Phone | 972 3 7177050 |
| Website | painreform.com |
Stock Details
| Ticker Symbol | PRFX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 1801834 |
| CUSIP Number | M77798201 |
| ISIN Number | IL0011651580 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Efraim Cohen-Arazi | Interim Chief Executive Officer and Director |
| Dr. Ehud Geller Ph.D. | Executive Chairman |
| Eyal Broder | Chief Financial Officer |
| Dr. Sigal Aviel eMBA, Ph.D. | Chief Operating Officer |
| Rita Keynan M.Sc. | Vice President of Pharmaceutical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 16, 2026 | 6-K | Report of foreign issuer |
| Sep 9, 2026 | 6-K | Report of foreign issuer |
| Sep 3, 2026 | EFFECT | Notice of Effectiveness |
| Sep 3, 2026 | POS AM | Post-Effective amendments for registration statement |
| Sep 3, 2026 | 6-K | Report of foreign issuer |
| Jul 27, 2026 | 6-K | Report of foreign issuer |
| Jul 21, 2026 | 6-K | Report of foreign issuer |
| Jul 15, 2026 | 6-K | Report of foreign issuer |
| Jul 8, 2026 | 6-K | Report of foreign issuer |
| Jun 29, 2026 | EFFECT | Notice of Effectiveness |